KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Cvs Health (CVS) over the last 17 years, with Q4 2025 value amounting to -$855.0 million.

  • Cvs Health's Change in Accured Expenses fell 7849.69% to -$855.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 15683.23%. This contributed to the annual value of $2.0 billion for FY2025, which is 15683.23% up from last year.
  • Per Cvs Health's latest filing, its Change in Accured Expenses stood at -$855.0 million for Q4 2025, which was down 7849.69% from $1.1 billion recorded in Q3 2025.
  • In the past 5 years, Cvs Health's Change in Accured Expenses ranged from a high of $6.5 billion in Q3 2022 and a low of -$2.4 billion during Q2 2024
  • In the last 5 years, Cvs Health's Change in Accured Expenses had a median value of $148.5 million in 2021 and averaged $466.5 million.
  • In the last 5 years, Cvs Health's Change in Accured Expenses surged by 906000.0% in 2021 and then tumbled by 63289.47% in 2024.
  • Over the past 5 years, Cvs Health's Change in Accured Expenses (Quarter) stood at $916.0 million in 2021, then tumbled by 199.13% to -$908.0 million in 2022, then surged by 44.16% to -$507.0 million in 2023, then grew by 5.52% to -$479.0 million in 2024, then tumbled by 78.5% to -$855.0 million in 2025.
  • Its Change in Accured Expenses stands at -$855.0 million for Q4 2025, versus $1.1 billion for Q3 2025 and -$118.0 million for Q2 2025.